TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 17, 2015, Pages 1902-1909

  Isakoff, Steven J ^a,b   Mayer, Erica L ^b,c   He, Lei ^a,b   Traina, Tiffany A ^f   Carey, Lisa A ^g   Krag, Karen J ^b,e   Rugo, Hope S ^h   Liu, Minetta C ⁱ   Stearns, Vered ^j   Come, Steven E ^b,d   Timms, Kirsten M ^k   Hartman, Anne Renee ^l   Borger, Darrel R ^a,b   Finkelstein, Dianne M ^a,b   Garber, Judy E ^b,c   Ryan, Paula D ^a,b   Winer, Eric P ^b,c   Goss, Paul E ^a,b   Ellisen, Leif W ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Myriad Genetics ^*  (United States)

^l Myriad Genetic Laboratories   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; MESSENGER RNA; PROTEIN P53; PROTEIN P63; PROTEIN P73; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DYSPNEA; ELECTROLYTE DISTURBANCE; EXPLORATORY RESEARCH; FATIGUE; FEBRILE NEUTROPENIA; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMIC INSTABILITY; GERMLINE MUTATION; HETEROZYGOSITY LOSS; HOMOLOGOUS RECOMBINATION; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOMAGNESEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; METASTATIC TRIPLE NEGATIVE BREAST CANCER; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHY; OPEN STUDY; OTOTOXICITY; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; MUTATION; PATHOLOGY; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HETEROZYGOTE; HUMANS; LOSS OF HETEROZYGOSITY; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84937145516     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.6660     Document Type: Article

References (23)

1. Kassam F, Enright K, Dent R, et al: Survival outcomes for patients with metastatic triplenegative breast cancer: Implications for clinical practice and trial design. Clin Breast Cancer 9:29-33, 2009
2. Hudis CA, Gianni L: Triple-negative breast cancer: An unmet medical need. Oncologist 16:1-11, 2011
3. Shah SP, Roth A, Goya R, et al: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486:395-399, 2012
4. Criscitiello C, Azim HA Jr, Schouten PC, et al: Understanding the biology of triple-negative breast cancer. Ann Oncol 23:vi13-vi18, 2012
5. Turner NC, Reis-Filho JS: Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 19:6380-6388, 2013
6. Turner NC, Tutt AN: Platinum chemotherapy for BRCA1-related breast cancer: Do we need more evidence? Breast Cancer Res 14:115, 2012
7. Byrski T, Gronwald J, Huzarski T, et al: Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 28:375-379, 2010
8. Silver DP, Richardson AL, Eklund AC, et al: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153, 2010
9. Byrski T, Dent R, Blecharz P, et al: Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14:R110, 2012
10. Popova T, Manié E, Rieunier G, et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 72:5454-5462, 2012
11. Abkevich V, Timms KM, Hennessy BT, et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107:1776-1782, 2012
12. Liu M, Mo QG, Wei CY, et al: Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 5:983-991, 2013
13. Isakoff SJ: Triple-negative breast cancer: Role of specific chemotherapy agents. Cancer J 16:53-61, 2010
14. McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23:9067-9072, 2005
15. Leong CO, Vidnovic N, DeYoung MP, et al: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370-1380, 2007
16. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
17. Lehmann BD, Bauer JA, Chen X, et al: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750-2767, 2011
18. Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010
19. Prat A, Parker JS, Karginova O, et al: Phenotypic and molecular characterization of the claudinlow intrinsic subtype of breast cancer. Breast Cancer Res 12:R68, 2010
20. Rakha EA, Elsheikh SE, Aleskandarany MA, et al: Triple-negative breast cancer: Distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2302-2310, 2009
21. Baselga J, Gómez P, Greil R, et al: Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 31:2586-2592, 2013
22. Carey LA, Rugo HS, Marcom PK, et al: TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triplenegative breast cancer. J Clin Oncol 30:2615-2623, 2012
23. Vollebergh MA, Lips EH, Nederlof PM, et al: Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res 16:R47, 2014